0
Home
Products
Degarelix – (214766-78-6)
Degarelix - (214766-78-6)

Degarelix – (214766-78-6)

Degarelix is a hor used in the treatment of advanced prostate cancer. It is a gonadotropin-releasing hormone (GnRH) receptor antagonist that works by binding to GnRH receptors in the pituitary gland, blocking the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This action leads to a rapid and sustained reduction in testosterone levels, which is crucial for slowing the growth of hormone-sensitive prostate tumors. Degarelix is administered via subcutaneous injection and is known for its immediate onset of action without causing the initial testosterone surge associated with GnRH agonists. Common side effects include injection site reactions, hot flashes, and weight gain. It was approved by the FDA in December 2008 and by the European Medicines Agency in February 2009.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

SKU: 214766-78-6
Categories: ,
Tags: , ,

Degarelix is a hor used in the treatment of advanced prostate cancer. It is a gonadotropin-releasing hormone (GnRH) receptor antagonist that works by binding to GnRH receptors in the pituitary gland, blocking the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This action leads to a rapid and sustained reduction in testosterone levels, which is crucial for slowing the growth of hormone-sensitive prostate tumors. Degarelix is administered via subcutaneous injection and is known for its immediate onset of action without causing the initial testosterone surge associated with GnRH agonists. Common side effects include injection site reactions, hot flashes, and weight gain. It was approved by the FDA in December 2008 and by the European Medicines Agency in February 2009.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
Sources:
https://en.wikipedia.org/wiki/Degarelix
https://pubchem.ncbi.nlm.nih.gov/compound/16136245
https://www.medchemexpress.com/Degarelix.html
https://www.medkoo.com/products/44745
https://www.mayoclinic.org/drugs-supplements/degarelix-subcutaneous-route/description/drg-20072529
https://medlineplus.gov/druginfo/meds/a609022.html#:~:text=Degarelix
Other Names

Firmagon, Uglypeptide1, SX0XJI3A11

IUPAC Name

(4S)-N-[4-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[4-(carbamoylamino)phenyl]-1-oxopropan-2-yl]amino]-3-oxopropyl]phenyl]-2, 6-dioxo-1, 3-diazinane-4-carboxamide

CAS

214766-78-6

Molecular Weight

1632.3

Molecular Formula

C82H103ClN18O16

SMILES

C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CC5=CN=CC=C5)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C8C=C7)NC(=O)C

Related products

No products in the cart.